Abstract 412P
Background
To study of cytogenetic changes in peripheral blood lymphocytes of patients with osteosarcoma.
Methods
Studies were conducted in peripheral blood samples of 196 patients with osteosarcoma (OS) aged from 10 to 45 years. The primary cytogenetic study of patients was carried out before their clinical examination.
Results
The analysis showed that after chemotherapy, 59.5% of patients had a full and partial effect. At 46.2%, the background level of chromosomal abnormalities was less than 5% (discriminatory or dividing level), but 2.5 times higher than the average level of chromosomal abnormalities in healthy individuals. The lack of effect was observed in 40.5% of patients, and their background chromosomal abnormalities were higher than discriminatory (5%) and 7.5 times higher than in healthy individuals. A comparative analysis of the effectiveness of the treatment and the average background level of Cr-disorders among patients in this group showed that 46.2% of patients with a positive effect from chemotherapy had an average level of Cr-disorders in peripheral blood lymphocytes 2.4 times lower, than in patients with a lack of effect from this therapy.
Conclusions
The analysis showed that in the absence of the effect of the treatment carried out, the background indicators of chromosomal aberrations are significantly higher than in healthy individuals or in individuals with good clinical effect. Consequently, according to the level of chromosome aberrations in the peripheral blood lymphocytes of patients with OS identified before the start of treatment, the therapeutic effect can be predicted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ronc.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract